Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Authors
Keywords
-
Journal
HEART
Volume -, Issue -, Pages heartjnl-2020-318060
Publisher
BMJ
Online
2021-02-27
DOI
10.1136/heartjnl-2020-318060
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
- (2020) Jagdeep S.S. Singh et al. DIABETES CARE
- Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
- (2020) Natalie A. Mordi et al. CIRCULATION
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress
- (2019) Guiping Luo et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
- (2019) Lin Shi et al. AMERICAN JOURNAL OF HYPERTENSION
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
- (2019) Michael E. Nassif et al. CIRCULATION
- Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
- (2019) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
- (2019) Peili Wu et al. HORMONE AND METABOLIC RESEARCH
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
- (2018) Russell L Esterline et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
- (2018) Franco Cosmi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardioprotective effects of autophagy: Eat your heart out, heart failure!
- (2018) Gaetano Santulli Science Translational Medicine
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Effects of intentional weight loss in patients with obesity and heart failure: a systematic review
- (2018) K. McDowell et al. Obesity Reviews
- Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
- (2018) Kwong-Man Ng et al. Scientific Reports
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Changes in body composition during SGLT2 inhibitor treatment and their relevance to the improvement of insulin sensitivity
- (2016) Hitomi Nakayama et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms Linking Inflammation to Insulin Resistance
- (2015) Li Chen et al. International Journal of Endocrinology
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- (2015) Lana Pinto et al. Diabetology & Metabolic Syndrome
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
- (2015) Jacob A Udell et al. Lancet Diabetes & Endocrinology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Cardiovascular remodelling in coronary artery disease and heart failure
- (2014) Gerd Heusch et al. LANCET
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
- (2013) Karl Swedberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decreased cardiac L-type Ca2+ channel activity induces hypertrophy and heart failure in mice
- (2011) Sanjeewa A. Goonasekera et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2
- (2010) Charles S. Hummel et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
- (2009) S. K. Banerjee et al. CARDIOVASCULAR RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started